Abstract:The revolutionary nanotechnology brings hope to posterior segment ocular diseases. This review delves into the challenges of conventional drug delivery and the advantages of diverse nanomaterials in enhancing drug stability, targeting, and permeability by targeting VEGF, ROS, macrophages. Focusing on the latest developments, this paper examines nanomedicine's potential to transform therapeutic approaches and improve global visual health. Funduscopic diseases, including diabetic retinopathy (DR) and age‐related macular degeneration (AMD), significantly impact global visual health, leading to impaired vision and irreversible blindness. Delivering drugs to the posterior segment of the eye remains a challenge due to the presence of multiple physiological and anatomical barriers. Conventional drug delivery methods often prove ineffective and may cause side effects. Nanomaterials, characterized by their small size, large surface area, tunable properties, and biocompatibility, enhance the permeability, stability, and targeting of drugs. Ocular nanomaterials encompass a wide range, including lipid nanomaterials, polymer nanomaterials, metal nanomaterials, carbon nanomaterials, quantum dot nanomaterials, and so on. These innovative materials, often combined with hydrogels and exosomes, are engineered to address multiple mechanisms, including macrophage polarization, reactive oxygen species (ROS) scavenging, and anti‐vascular endothelial growth factor (VEGF). Compared to conventional modalities, nanomedicines achieve regulated and sustained delivery, reduced administration frequency, prolonged drug action, and minimized side effects. This study delves into the obstacles encountered in drug delivery to the posterior segment and highlights the progress facilitated by nanomedicine. Prospectively, these findings pave the way for next‐generation ocular drug delivery systems and deeper clinical research, aiming to refine treatments, alleviate the burden on patients, and ultimately improve visual health globally.

Nanomedicine in the Application of Uveal Melanoma

Nanoparticles in the Ocular Drug Delivery

Nanoceria for Ocular Diseases: Recent Advances and Future Prospects

Nanomaterials in the Diagnosis and Treatment of Ophthalmic Diseases

Nano-based Drug Delivery Systems for the Treatment of Non-Infectious Uveitis

Potential of miRNA-Based Nanotherapeutics for Uveal Melanoma

A Long-Acting Curcumin Nanoparticle/In Situ Hydrogel Composite for the Treatment of Uveal Melanoma

Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases

Ocular Nanomedicine

Applications of nanomaterials in anti-VEGF treatment for ophthalmic diseases

Overview of Recent Advances in Nano-Based Ocular Drug Delivery

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases (Adv. Sci. 32/2024)

A Novel Stimuli‐Responsive Injectable Antibacterial Hydrogel to Achieve Synergetic Photothermal/Gene‐Targeted Therapy towards Uveal Melanoma

Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy

Ultrasound-enhanced nano catalyst with ferroptosis-apoptosis combined anticancer strategy for metastatic uveal melanoma

Nanomedicines for the Treatment of Glaucoma: Current Status and Future Perspectives

Recent developments in nanomedicine for melanoma treatment

Nano-mediated strategy: recent advance in the application of drug delivery systems in melanoma treatment and diagnosis

Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma

Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems